Business Wire

Mary Kay Inc. Named Among Most Reputable Global Employers in Reputation Institute’s 2019 Workplace Study

29.7.2019 18:00:00 EEST | Business Wire | Press release

Share

Mary Kay Inc. is proud to be recognized in the 2019 Global Workplace 100 Study by Reputation Institute (Ri) as one of the world’s most reputable employers. Mary Kay is ranked number 42 among the top 100 global companies on the list.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190729005477/en/

“Our reputation among employees and customers is based on the foundation Mary Kay Ash established when she began her dream company in 1963,” said Melinda Foster Sellers, Chief People Officer at Mary Kay Inc. “She envisioned a company based on the Golden Rule that made the world a better place through corporate responsibility, innovation, ethical business practices and people-first management—all factors that contributed to our success in this year’s Reputation Institute study. We’re honored to be named among the most reputable employers from around the world in 2019.”

In the study, researchers at Reputation Institute—a leading provider of reputation measurement and management services—surveyed more than 230,000 individuals in 15 countries. Reputation Institute measured companies based on professional development, total rewards, work environment, market leadership, products and responsibility.

According to the research, over the last year, willingness to work for Mary Kay increased by 6.2 percent, the largest improvement among all the companies measured in the Global RepTrak® 100 study. Mary Kay outranks other global powerhouse brands in a variety of industries across the globe.

“Mary Kay is a rising star in the reputation study—showing the biggest improvement in the ‘willingness to work for’ category of all companies measured,” said Stephen Hahn-Griffiths, Chief Reputation Officer at Ri. “Companies like Mary Kay are reaping the benefits of building workplace cultures that foster inclusion while demonstrating concern for the health and well-being of its employees.”

This is the latest in the series of accolades Mary Kay has received highlighting its position as a global employer of choice. Other recent awards include:

  • Top 10 Global CEOs: Reputation Institute named Chairman and CEO David Holl among the top 10 most reputable chief executives in the world according to its CEO RepTrak® 2019.
  • Best Midsize Employer 2019: Recognized by Forbes as one of America’s Best Midsize Employers 2019. Mary Kay is ranked number 97 of the 500 companies on the list.
  • Best Employer for Diversity 2019: Recognized by Forbes as one of America’s Best Employers for Diversity 2019. Mary Kay is ranked number 150 of the 500 companies on the list.
  • Global Excellence in the Workplace: Mary Kay Spain and Mary Kay Poland earned the 2018 AON Best Employers Award, recognizing organizations demonstrating excellence in the workplace. Mary Kay China and Mary Kay Mexico picked up the honor in 2017.
  • Family-Friendly Employer 2018: Mary Kay Hong Kong was recognized by Home Affairs Bureau as a top family-friendly employer.
  • Chinese Enterprise Health Management Top 10 Employers 2018: China International Intellectech Corporation honored Mary Kay China.

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 55 years ago with three goals: offer rewarding opportunities for women, provide irresistible products and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to researching the science behind beauty and to manufacturing cutting-edge skin care, color cosmetics, fragrances and nutritional supplements. Through The Mary Kay FoundationSM, the company has awarded more than $78 million to cancer research and domestic violence shelters. Mary Kay Ash’s original vision continues to shine—one lipstick at a time.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 02:35:00 EEST | Press release

Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Capability of Next Generation Earth Observation Satellites Project Title: Source-Specific CO2 Emission and Uptake Monitoring through Satellite Constellation and Ai

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye